https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54994 Wed 27 Mar 2024 16:38:54 AEDT ]]> Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41947 Wed 22 Mar 2023 14:31:19 AEDT ]]> Bladder carcinoma in situ (CIS) in Australia: a rising incidence for an under-reported malignancy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18447 50 years, showing a rapid increase in the rates of CIS from 2001. * There was an 11% (P = 0.04) and 14% (P = 0.02) annual increase in incidence of CIS in men and women and these rates increased with age. Conclusions * National data (AIHW) substantially underestimate the incidence of CIS in the Australian population. * Patient level data suggest CIS rates are rapidly increasing in Australia despite high treatment rates. * Closer surveillance and awareness of these high rates warrants further study and we recommend that CIS be considered a reportable disease.]]> Sat 24 Mar 2018 07:59:46 AEDT ]]> Prostate cancer screening in primary health care: the current state of affairs https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27599 Mon 13 Jul 2020 13:36:18 AEST ]]>